Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Human Epidermal Growth Factor Market Grown from 2024 to 2025?

The human epidermal growth factor market has seen considerable growth in the past few years. The market, which was worth $2.18 billion in 2024, is projected to reach $2.39 billion in 2025, growing at a compound annual growth rate of 9.3%. The increase during the historical period can be attributed to the rising aging population who are more susceptible to skin conditions, increased support and funding from governments for biopharmaceutical advancements, a surge in diabetes cases leading to more incidents of chronic wounds, increased partnerships between pharmaceutical firms and research institutions, and the growing preference of consumers for non-invasive skincare options.

What Growth Rate Is Anticipated for the Human Epidermal Growth Factor Market in the Coming Years?

The human epidermal growth factor market is predicted to experience a robust growth in the years to come. It is anticipated to reach a value of $3.37 billion by 2029, with an impressive compound annual growth rate (CAGR) of 9.0%. This growth during the forecast period is likely to be driven by factors such as growing demand for regenerative medicine and procedures related to wound healing, increased instances of chronic skin disorders and injuries, heightened understanding about anti-aging and skincare items containing hegf, boosted investment in the field of biotech research and development, along with growing implementation of customised medicine and targeted treatments. Key trends in the forecast period incorporate advancements in recombinant dna technology, progress in protein engineering to enhance the stability and efficacy of hegf, the technological incorporation of nanotechnology, breakthroughs in bioprocessing tactics, and progress in cell culture technology.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24564&type=smp

Who Are the Leading Companies in the Human Epidermal Growth Factor Market?

Major companies operating in the human epidermal growth factor market are Pfizer Inc., Johnson & Johnson Services Inc, F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, AstraZeneca plc, Novartis AG, GlaxoSmithKline Plc, Amgen Inc., Lonza Group AG, STEMCELL Technologies, Abcam plc., BioLegend Inc., Bharat Biotech International Limited, RayBiotech Inc., Enzo Life Sciences Inc., Neocutis S.A, Proteintech Group Inc., Creative BioMart Co. Ltd., Abbkine Scientific Co. Ltd.

What Are the Key Drivers of the Human Epidermal Growth Factor Market?

The growth of the human epidermal growth factor market is anticipated to surge due to the increasing utilization of personalized medicine. This healthcare approach, which customizes treatments based on a person’s genetic profile, lifestyle, and environment, allows for more precise and efficient healthcare. Advances in genomic technologies have facilitated personalized medicine by allowing faster and more accurate identification of individual genetic profiles. HER2 role in personalized medicine is vital as it enables the categorization of tumors based on HER2 protein overexpression, which aids in selecting the appropriate targeted therapies. This not only results in improved treatment outcomes but also decreases unnecessary side effects. For example, in 2022, the Personalized Medicine Coalition, a US professional membership organization, reported that 34% of all new approved therapies comprised of 12 new personalized medicines. This was a considerable increase from previous years. Consequently, the surge in the personalized medicine application is driving the human epidermal growth factor market’s growth. Also, the human epidermal growth factor market is anticipated to experience significant growth due to the mounting number of clinical trials, leading to the demand for improved wound healing therapies. Clinical trials are required to assess the safety, effectiveness, and potential side effects of medical treatments or interventions. There’s a rising demand for these trials owing to the requirement for personalized and innovative treatments that necessitate thorough safety and efficacy testing. Human epidermal growth factor (hEGF) is a critical component in these trials as it fosters cell growth and tissue repair. This allows for evaluation of therapies for conditions such as wound healing and skin regeneration. For example, according to a report by the Association of the British Pharmaceutical Industry, a London-based trade association, industry clinical trials in the UK saw a 15% increase in annual recruitment from 36,722 participants in 2021-22 to 42,088 in 2022-23. Therefore, the escalating number of clinical trials is propelling the human epidermal growth factor market’s growth.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24564&type=smp

What Are the Key Market Segments in the Human Epidermal Growth Factor Industry?

The human epidermal growth factor market covered in this report is segmented –

1) By Product Type: Recombinant Human Epidermal Growth Factor, Natural Human Epidermal Growth Factor

2) By Formulation: Injectable Form, Topical Form, Oral Form

3) By Distribution Channel: Direct Sales, Online Pharmacies, Retail Pharmaceis, Hospital Pharmacies, Specialty Clinics

4) By Application: Dermatology, Oncology, Opthalmology, Wound Healing, Cosmetic Procedures

5) By End-User: Hospitals, Clincs, Research Institutes, Other End Users

Subsegments:

1) By Recombinant Human Epidermal Growth Factor: Injectable solutions, Oncology therapeutics, Eye drops, Wound healing agents

2) By Natural Human Epidermal Growth Factor: Plasma-derived products, Colostrum-based products, Amniotic fluid-derived products, Salivary-derived formulations

What Are the Latest Trends in the Human Epidermal Growth Factor Market?

Leading firms in the human epidermal growth factor marketplace are placing emphasis on producing technological innovations such as AI-driven immunohistochemistry (IHC) scoring systems to increase the accuracy, speed, and repeatability of biomarker detection and cancer diagnosis. The AI-driven immunohistochemistry (IHC) scoring technology implicates the use of artificial intelligence protocols to autonomously examine and quantify protein levels in tissue samples stained via IHC, boosting reliability, consistency, and expedition in diagnostic pathology. For example, in September 2023, Ibex Medical Analytics, a company based in Israel, introduced their product, Ibex Breast HER2. This enhances the accuracy and consistency of HER2 biomarker scoring in cases of breast cancer, particularly in problematic HER2-low instances, facilitating the optimization of treatment procedures and bettering patient results. The key advantages of this are highly precise, repeatable, and effectual HER2 IHC scoring, aiding pathologists in reaching assured, impartial choices for the selection of targeted therapy.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/human-epidermal-growth-factor-global-market-report

What Are the Key Regional Markets in the Human Epidermal Growth Factor Industry?

North America was the largest region in the human epidermal growth factor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human epidermal growth factor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24564

This Report Delivers Insight On:

1. How big is the human epidermal growth factor market, and how is it changing globally?

2. Who are the major companies in the human epidermal growth factor market, and how are they performing?

3. What are the key opportunities and risks in the human epidermal growth factor market right now?

4. Which products or customer segments are growing the most in the human epidermal growth factor market?

5. What factors are helping or slowing down the growth of the human epidermal growth factor market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model